E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Ahmad A TarhiniSandra J LeeXiaoxue LiUma N M RaoArun NagarajanMark R AlbertiniJerry W MitchellStuart J WongMark A TaylorNoel LaudiPhu V TruongRobert M ConryJohn M KirkwoodPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Although PFS was increased, the differences resulting from adding interferon-α or a higher dose of ipilimumab did not reach statistical significance and do not outweigh the added toxicity risks.